mBos TKA System vs Johnson & Johnson Ottava in 2026

mBos TKA System

The Monogram mBos TKA System is a robotic total-knee-arthroplasty platform from Monogram Technologies, a Zimmer Biomet subsidiary since October 2025. It is the autonomy-boundary case of DEPLOY's surgical cluster: unlike the AI-augmented, surgeon-controlled systems (Stryker Mako, Smith+Nephew CORI, Zimmer Biomet ROSA), where the surgeon makes the cuts, the cleared mBos is semi-autonomous, with a robotic arm (built on a KUKA arm) executing the bone cuts itself under AI control within a surgeon-approved, patient-specific CT-based plan and active surgeon supervision.

There is no consumer price: it is pre-commercial enterprise surgical equipment that has not sold any units. Several verified-vs-claimed cap-flags matter. It received FDA 510(k) clearance on March 17, 2025, but the exact K-number could not be independently verified, and the 'semi-autonomous' characterization is sourced to Zimmer Biomet and trade coverage rather than the FDA letter (Monogram's own clearance release described it more softly as robotic-assisted TKA).

A separate fully-autonomous, hands-free, saw-based version is not FDA cleared and remains in development, targeted around late 2027 or 2028; its first live-patient procedure (July 26, 2025, Ahmedabad, India) was under an India CDSCO 102-procedure investigation, not US FDA, a single index case with no verified peer-reviewed outcomes. Monogram was founded by orthopedic surgeon Dr.

Doug Unis (chief medical officer and founder, not CEO; the pre-acquisition CEO was Benjamin Sexson) and was acquired by Zimmer Biomet at about $168M enterprise value plus contingent value rights, with commercialization alongside Zimmer Biomet implants targeted for early 2027. The registry records it at research maturity: cleared but pre-commercial, with its headline fully-autonomous capability still in development.

Johnson & Johnson Ottava

J&J MedTech's Ottava is a soft-tissue general-surgery robotic platform with four arms integrated into the operating table, announced in 2020. It is pre-market: J&J submitted a De Novo request to the FDA in January 2026, and Ottava is not authorized to be marketed. DEPLOY classifies it research tier: J&J's corporate scale does not translate into verified surgical-robotics deployment, because the gating event (FDA clearance) has not occurred.

By the framework, Ottava sits at the same research tier as far smaller pre-market entrants. There is no price; it is not sold.